Back to top

Piper Sandler Sticks to Their Buy Rating for Corcept Therapeutics (CORT)

Piper Sandler analyst David Amsellem maintained a Buy rating on Corcept Therapeutics today and set a price target of $88.00. According to TipRanks,...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Corcept Therapeutics Incorporated (CORT)